Asia Pacific Inhalable Drugs Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$6,546.9

Forecast, 2030 (US$M)

$10,734.4

CAGR, 2024 - 2030

7.3%

Report Coverage

Asia Pacific

Asia Pacific inhalable drugs market, 2018-2030 (US$M)

Related Markets

Global Inhalable Drugs Industry Outlook

North America Inhalable Drugs Market Outlook

Europe Inhalable Drugs Market Outlook

Latin America Inhalable Drugs Market Outlook

MEA Inhalable Drugs Market Outlook

Asia Pacific inhalable drugs market highlights

The Asia Pacific inhalable drugs market generated a revenue of USD 6,546.9 million in 2023.
The market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
In terms of segment, aerosol was the largest revenue generating drug class in 2023.
Aerosol is the most lucrative drug class segment registering the fastest growth during the forecast period.

Asia Pacific data book summary

Market revenue in 2023	USD 6,546.9 million
Market revenue in 2030	USD 10,734.4 million
Growth rate	7.3% (CAGR from 2023 to 2030)
Largest segment	Aerosol
Fastest growing segment	Aerosol
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Aerosol
Key market players worldwide	AstraZeneca PLC, Sanofi SA, Philip Morris International Inc, Viatris Inc, GSK PLC, Boehringer Ingelheim, Cipla Ltd DR

Other key industry trends

In terms of revenue, Asia Pacific region accounted for 19.6% of the global inhalable drugs market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 10,734.4 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Inhalable Drugs Market Scope

Inhalable drugs market segmentation & scope

Drug Class

Aerosol

Dry powder formulation

Spray

Formulation

Respiratory diseases

Non-respiratory diseases

Regions

Latin America

Europe

North America

Middle East & Africa

Asia Pacific

Countries

Argentina

Brazil

Mexico

Germany

France

Italy

Spain

Sweden

Denmark

Norway

U.S.

Canada

UAE

South Africa

Saudi Arabia

Kuwait

Australia

China

India

Japan

South Korea

Thailand

Inhalable Drugs Market Companies

Name	Profile	# Employees	HQ	Website

Asia Pacific inhalable drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inhalable drugs market will help companies and investors design strategic landscapes.

Aerosol was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific inhalable drugs market based on aerosol covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to Asia Pacific inhalable drugs market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific inhalable drugs market databook

Our clientele includes a mix of inhalable drugs market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific inhalable drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific inhalable drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list